+ Watch VPHM
on My Watchlist
A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.
ViroPharma markets two drugs: Vancocin for clostridium difficile infections, and Cinryze for rare hereditary angioedema. The company's investment potential is tied to how fast the latter can replace declining sales from the former.Read my full CAPS review here:http://caps.fool.com/Blogs/viropharma-vphm-a-tale-of/433135
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions